---
document_datetime: 2024-11-18 16:54:29
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pylclari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: pylclari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.6689946
conversion_datetime: 2025-12-28 18:06:30.490978
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pylclari

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0006/G            | This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The | 15/11/2024                          |                                             | Annex II, Labelling and PL       |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products   |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004 | Update of sections 4.8 and 11 of the SmPC in order to update the dosimetry methodology, based on results obtained with a new generation software and in accordance with the recommendations of ICRP 103, in order to fulfil a recommendation (REC). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                | 18/07/2024 | SmPC, Labelling and PL | Dosimetry methodology: The time-integrated activity in source tissue was obtained from longitudinal imaging data. Contours or volumes of interest (VOIs) were typically drawn around different activity-containing organs that were identified on each image at each time-point. The S-value was obtained by Monte Carlo simulation. The absorbed doses calculation was performed on 3D-RD-S software. The resulting effective dose was calculated according to ICRP 103. The effective dose resulting from the administration of a maximal recommended activity of 360 MBq for an adult weighing 70 kg is about 4.4 mSv. For an administered activity of 360 MBq, the typical radiation doses to the critical organs (kidneys, liver and |

<div style=\"page-break-after: always\"></div>

|                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                            | spleen) are 44.6 mGy, 14 mGy and 10.2 mGy respectively. For more information, please refer to the Summary of Product Characteristics.   |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/97/20 2311 | Periodic Safety Update EU Single assessment - piflufolastat (18F)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/06/2024 | n/a |                            | PRAC Recommendation - maintenance                                                                                                       |
| IB/0003/G        | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - | 27/03/2024 |     | Annex II, Labelling and PL |                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, and sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, and sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, and sterile medicinal products   | aseptically   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|

<div style=\"page-break-after: always\"></div>

|           | immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging   |            |                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|
| IB/0001/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products                                                                                                                                                                                                                                                                                                                                                                                        | 27/11/2023 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| B.II.b.1.f - Replacement manufacturing site for manufacturing process manufacturing operation(s) release, batch control, sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.1.f - Replacement manufacturing site for manufacturing process manufacturing operation(s) release, batch control, sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.1.a - Replacement manufacturing site for site B.II.b.1.a - Replacement manufacturing site for site B.II.b.1.a - Replacement manufacturing site for site B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| arrangements and quality Including batch control/testing B.I.a.1.a - Change in the starting material/reagent/intermediate proposed manufacturer pharmaceutical group as manufacturer B.I.a.1.a - Change in the starting material/reagent/intermediate proposed manufacturer pharmaceutical group as manufacturer B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.II.b.2.a - Change to arrangements and quality Replacement/addition of control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition of control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition of control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition of control/testing takes place   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| arrangements and quality Replacement/addition control/testing takes place B.II.d.2.d - Change in product - Other changes (including replacement B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.z - Administrative change - Other variation   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|